Eudragit coating of chitosan-prednisolone conjugate microspheres and in vitro evaluation of coated microspheres

Drug Development and Industrial Pharmacy

Volumn 33, Issue 8, 2007, Pages 848-854

  Onishi, Hiraku ^a   Oosegi, Tomoko ^a   Machida, Yoshiharu ^a   McGinity, James W ^b  

^a HOSHI UNIVERSITY   (Japan)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Chitosan prednisolone conjugate microspheres; Drug release; Eudragit coating; Particle characteristics; pH

Indexed keywords

CHITOSAN; EUDRAGIT; MICROSPHERE; PREDNISOLONE;

ARTICLE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SCREENING; PARTICLE SIZE; PH MEASUREMENT;

ACRYLATES; ANTI-INFLAMMATORY AGENTS; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL TRANSIT; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PARTICLE SIZE; POLYMERS; PREDNISOLONE; TABLETS, ENTERIC-COATED;

EID: 34548314302     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701377904     Document Type: Article

References (25)

1. Anderson, B. D., Conradi, R. A., Knuth, K. E., & Nail, S. L. (1985). Strategies in the design of solution-stable, water-soluble prodrugs II: Properties of micellar prodrugs of methylprednisolone. J. Pharm. Sci., 74(4), 375-381.
2. Anderson, B. D., & Taphouse, V. (1981). Initial rate studies of hydrolysis and acyl migration in methylprednisolone 21-hemisuccinate and 17-hemisuccinate. J. Pharm. Sci., 70(2), 181-186.
3. Danese, S., & Fiocchi C. (2006). Etiopathogenesis of inflammatory bowel diseases. World J. Gastroenterol., 12(30), 4807-4812.
4. Fiocchi, C. (2002). Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy. Minerva Gastroenterol. E Dietol., 48(3), 215-226.
5. Gionchetti, P., Rizzello, F., Habal, F., Morselli, C., Amadini, C., Romagnoli, R., & Campieri, M. (2003). Standard treatment of ulcerative colitis. Dig. Dis., 21(3), 157-167.
6. Kawanami, C., Oshima, C., Ikada, Y., & Chiba, T. (2000). Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J. Pharmacol. Exp. Ther., 292(1), 15-21.
7. Klotz, U. (1985). Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin. Pharmacokinet., 10(4), 285-302.
8. Lamprecht, A., Schafer, U., & Lehr, C. M. (2000). Microparticle targeting to the inflamed colonic mucosa for the treatment of inflammatory bowel disease: in vivo results from rat. AAPS Pham. Sci., 2(S1), Abstract 1930.
9. Lamprecht, A., Schafer, U., & Lehr, C. M. (2001c). Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res., 18(6), 788-793.
10. Lamprecht, A., Ubrich, N., Yamamoto, H., Schafer, U., Takeuchi, H., Lehr, C. M., Maincent, P., & Kawashima, Y. (2001b). Design of rolipram-loaded nanoparticles: comparison of two preparation methods. J. Control. Release, 71, 297-306.
11. Lamprecht, A., Ubrich, N., Yamamoto, H., Schafer, U., Takeuchi, H., Maincent, P., Kawashima, Y., & Lehr, C. M. (2001a). Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther., 299(2), 775-781.
12. Larouche, J., Morais, J., Picard, M., Lambert, C., Spenard, J., Landriault, H., Kennedy, G., & Poitras, P. (1995). Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine. Aliment. Pharmacol. Ther., 9(3), 315-320.
13. McLeod, A. D., Friend, D. R., & Tozer, T. N. (1993). Synthesis and chemical stability of glucocorticoid-dextran esters: Potential prodrugs for colon-specific delivery. Int. J. Pharm., 92, 105-114.
14. Mehvar, R., Dann, R. O., & Hoganson, D. A. (2000) Kinetics of hydrolysis of dextran-methylprednisolone succinate, a macromolecular prodrug of methylprednisolone, in rat blood and liver lysosomes. J. Control. Release., 68(1), 53-61.
15. Nakase, H., Okazaki, K., Tabata, Y., Uose, S., Ohana, M., Uchida, K., Matsushima, Y., Yano, H., Hirayama, F., Kamada, M., Arima, H., & Uekama, K. (2002). Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: Alleviation of systemic side effect after oral administration. J. Control. Release, 79, 103-112.
16. Onishi, H., Oosegi, T., Machida, Y., & McGinity J. W. (2005). Preparation and in vitro evaluation of chitosan microspheres containing prednisolone: comparison of simple and conjugate microspheres. Drug Dev. Ind. Pharm., 31(7), 597-605.
17. Sakuma, S., Sudo, R., Suzuki, N., Kikuchi, H., Akashi, M., & Hayashi, M. (1999). Mucoadhesion of polystyrene nanoparticles having surface hydrophilic polymeric chains in the gastrointestinal tract. Int. J. Pharm., 177, 161-172.
18. Shimoda, J., Onishi, H., & Machida, Y. (2001). Bioadhesive characteristics of chitosan microspheres to the mucosa of rat small intestine. Drug Dev. Ind. Pharm., 27(6), 567-576.
19. Tabata, Y., Inoue, Y., & Ikada, Y. (1996). Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine, 14, 1677-1685.
20. Tozaki, H., Fujita, T., Komoike, J., Kim, S. I., Terashima, H., Muranishi, S., Okabe, S., & Yamamoto, A. (1999a). Colon-specific delivery of budesonide with azopolymer-coated pellets: Therapeutic effects of budesonide with a novel dosage form against 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats. J. Pharm. Pharmacol., 51(3), 257-261.
21. Tozaki, H., Fujita, T., Odoriba, T., Terabe, A., Okabe, S., Muranishi, S., & Yamamoto, A. (1999b). Validation of a pharmacokinetic model of colon-specific drug delivery and the therapeutic effects of chitosan capsules containing 5-aminosalicylic acid on 2,4,6-trinitrobenzenesulphonic acidi-nduced colitis in rats. J. Pharm. Pharmacol., 51(10), 1107-1112.
22. Tozaki, H., Komoike, J., Tada, C., Maruyama, T., Terabe, A., Suzuki, T., Yamamoto, A., & Muranishi, S. (1997). Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J. Pharm. Sci., 86(9), 1016-1021.
23. Tozaki, H., Odoriba, T., Okada, N., Fujita, T., Terabe, A., Suzuki, T., Okabe, S., Muranishi, S., & Yamamoto, A. (2002). Chitosan capsules for colon-specific drug deliver: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J. Control. Release, 82, 51-61.
24. Van Der Lubben, I. M., Konings, F. A., Borchard, G., Verhoef, J. C., & Junginger, H. E. (2001). In vivo uptake of chitosan microparticles by murine Peyer's patches: visualization studies using confocal laser scanning microscopy and immunohistochemistry. J. Drug Target, 9(1), 39-47.
25. Watts, P. J., Barrow, L., Steed, K. P., Wilson, C. G., Spiller, R. C., Melia, C. D., & Davies, M. C. (1992). The transit rate of different sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis. Int. J. Pharm., 87, 215-221.